blinatumomab   Click here for help

GtoPdb Ligand ID: 7384

Synonyms: Blincyto® | bscCD19xCD3 | MEDI-538 | MT-103 | MT103 [2]
Approved drug Immunopharmacology Ligand
blinatumomab is an approved drug (FDA (2014), EMA (2015))
Compound class: Antibody
Comment: Blinatumomab is a monoclonal antibody with anti-cancer effects. Its mechanism of action classifies this antibody as a member of the bi-specific T-cell engager (BiTE®) group of engineered antibodies. It was the first biologic of this class to gain clinical approval.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Click here for help
Immunopharmacology Comments
Blinatumomab is an immuno-oncology agent.
Immunopharmacology Disease
Disease X-Refs Comment References
Acute lymphocytic leukemia (ALL) OMIM: 613065
Approved specifically for Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia (B-cell ALL), an uncommon form of ALL.